InsidersTradesSigma
Follow the Glycomimetics INC stock price and the full insider trade history of the company, a listed equity based in United States. Shares are listed on the US market, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, Glycomimetics INC has logged 48 public disclosures. The latest transaction was reported on 17 June 2025 (J). Among the most active insiders: Invus Public Equities, L.P.. Every trade is accessible without an account.
48
Insider Decl.
n/a
Thresholds
€3m
18 ops.
Buy Volume
€1m
11 ops.
Sell Volume
36Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 17 June 2025
Declarations48 total
657,308 sharesCommon StockSEC:0000921895-25-001784:0
61,488 shares@ US$0.18210.4% of flowCommon StockSEC:0000950170-24-094800:0
164,523 shares@ US$0.18841.2% of flowCommon StockSEC:0000950170-24-092864:0
63,564 shares@ US$0.21620.5% of flowCommon StockSEC:0000950170-24-090910:0
258,335 shares@ US$0.24172.4% of flowCommon StockSEC:0000950170-24-088020:0
190,000 shares@ US$0.25329.7% of flowCommon StockSEC:0001415889-24-017978:0
Canonical exit: 18 Sept 2024 (T+90)
17,500 shares@ US$0.247711.7% of flowCommon StockSEC:0001415889-24-017623:0
Canonical exit: 16 Sept 2024 (T+90)
4,584 shares@ US$3.0033.4% of flowCommon StockSEC:0001415889-24-009744:0
5,209 shares@ US$3.0015.6% of flowCommon StockSEC:0001415889-24-009745:0
3,334 shares@ US$3.0033.4% of flowCommon StockSEC:0001415889-24-009743:0
4,238 shares@ US$2.3632.5% of flowCommon stockSEC:0001209191-24-000068:0
5,827 shares@ US$2.3632.5% of flowCommon stockSEC:0001209191-24-000067:0
5,191 shares@ US$2.366.6% of flowCommon stockSEC:0001209191-24-000069:0
9,167 shares@ US$1.5034.1% of flowCommon stockSEC:0001209191-23-051449:0
6,667 shares@ US$1.5034.1% of flowCommon stockSEC:0001209191-23-051390:0
8,167 shares@ US$1.506.9% of flowCommon stockSEC:0001209191-23-051392:0
35,000 shares@ US$1.3810.9% of flowCommon StockSEC:0001209191-23-050476:0
Canonical exit: 20 Dec 2023 (T+90)
21,000 shares@ US$0.6032.3% of flowCommon StockSEC:0001209191-23-033675:0
3,700 shares@ US$1.9519.3% of flowCommon StockSEC:0001209191-23-030636:0
30,000 shares@ US$1.5645.8% of flowCommon StockSEC:0001209191-23-028816:0
Canonical exit: 8 Aug 2023 (T+90)
13,500 shares@ US$1.57100.0% of flowCommon StockSEC:0001209191-23-028305:0
Canonical exit: 6 Aug 2023 (T+90)
100,000 shares@ US$1.706.7% of flowCommon StockSEC:0000899243-23-006426:0
Canonical exit: 25 May 2023 (T+90)
50,000 shares@ US$1.853.6% of flowCommon StockSEC:0000899243-23-006027:0
Canonical exit: 22 May 2023 (T+90)
1,000,000 shares@ US$2.155883.7% of flowCommon StockSEC:0000899243-23-005502:0
Canonical exit: 16 May 2023 (T+90)
11,451 shares@ US$3.24191.4% of flowCommon StockSEC:0000899243-23-004819:0
Canonical exit: 10 May 2023 (T+90)
25 of 48 declarations
关于 Glycomimetics INC
GlycoMimetics Inc.（股票代码：GLYC）是一家在美国纳斯达克市场上市的生物技术公司，专注于发现和开发基于糖生物学的疗法。该公司总部位于马里兰州罗克维尔，其科学定位围绕一个专有的化学平台，旨在创建所谓的糖模拟分子，旨在调节严重疾病（特别是癌症和炎症）中碳水化合物介导的识别途径。从历史上看，GlycoMimetics 是一家后期临床生物技术公司，而非商业化阶段的制药公司，其研究驱动模式以少数内部开发的候选药物为中心。([ir.glycomimetics.com](https://ir.glycomimetics.com/?utm_source=openai)) 该公司成立于 2000年代初期，以其肿瘤学项目而闻名，特别是 uproleselan，一种在急性髓系白血病和其他血液系统癌症中研究的 E-选择素拮抗剂。它还推进了早期的候选药物，如 GMI-1271 和 GMI-1359，这反映了围绕具有在利基治疗领域实现差异化潜力的专业机制构建的战略。对于投资者而言，这是一个重要的点：GlycoMimetics 类似于一家临床阶段的平台生物技术公司，其估值主要由试验执行、监管里程碑以及主要资产的潜在未来商业价值驱动，而非经常性产品收入。([ir.glycomimetics.com](https://ir.glycomimetics.com/news-releases/news-release-details/glycomimetics-announces-results-pivotal-phase-3-study?utm_source=openai)) 从竞争角度来看，GlycoMimetics 在一个高度拥挤的环境中运营，其中包括大型制药公司、专注于肿瘤学的生物技术公司和资金更充足的同行。其理论优势来自于其专有的糖生物学专业知识和科学专业化，但其规模较小使其容易受到临床挫折、融资压力和战略不确定性的影响。最近的一项重大进展是 2024年末宣布与 Crescent Biopharma 达成的收购协议，随后股东于 2025年6月批准了拟议的合并以及董事会批准的 1股拆 100股反向股票分割。投资者关系网站现在声明“GlycoMimetics 现为 Crescent Biopharma”，这表明对于此前以 GLYC 交易的公司而言，这是一次重大的公司转型。([ir.glycomimetics.com](https://ir.glycomimetics.com/news-releases/news-release-details/glycomimetics-enters-acquisition-agreement-crescent-biopharma?utm_source=openai)) 从地理上看，该业务主要位于美国，核心运营和公司领导层在马里兰州，并在美国纳斯达克上市。最近的文件还强调了小盘生物技术投资的实际情况，包括交易所合规问题和资本结构管理。因此，对于法语投资者而言，该股票应被视为一个高风险、高选择性的美国生物技术故事，其近期历史主要由与 Crescent Biopharma 的战略合并过程和相关的公司品牌重塑主导，而非产品商业化。([sec.gov](https://www.sec.gov/Archives/edgar/data/1253689/000155837025007780/glyc-20250331x10q.htm?utm_source=openai))
